More than a decade after Merck’s Keytruda and BMS’ Yervoy ushered in the immuno-oncology revolution, the space is at a ...

Oqory’s planned reverse merger with fellow antibody-drug conjugate (ADC) company Vincerx Pharma has fallen apart at the last ...

Pharmaceutical scientists at the National University of Singapore (NUS) have developed a novel chemical reaction that enables the precise functionalization of peptides and proteins.

Akeso begins patient enrolment in phase I trial of AK138 D1 for the treatment of advanced malignancies in Australia: Hong Kong Saturday, March 1, 2025, 12:00 Hrs [IST] Akeso, Inc.

Approval would expand the use of Enhertu to breast cancer patients with nearly undetectable HER2 levels in their tumors.

Pharmaceutical scientists at the National University of Singapore (NUS) have developed a novel chemical reaction that enables ...

ORLANDO, FLORIDA / ACCESS Newswire / February 28, 2025 / RedChip Companies will air interviews with Calidi Biotherapeutics, Inc. (NYSE American:CLDI) and OS Therapies Inc. (NYSE American:OSTX) on the ...

The FDA approved the investigational new drug application for a phase 1 trial of ADCE-T02 in advanced solid tumors.

RedChip Companies will air interviews with Calidi Biotherapeutics, Inc. (NYSE American:CLDI) and OS Therapies Inc. (NYSE American:OSTX) on the RedChip Small Stocks, Big Money™ show, a sponsored ...

Duality Biologics, a Chinese biotech specializing in antibody-drug conjugates (ADCs), has opted not to move forward at this ...

These product candidates include numerous innovative bispecific antibodies and antibody-drug conjugates. They also discuss clinical phase transition and overall approval success rates for antibody ...

The European Medicines Agency (EMA) committee (CHMP) has recommended approving trastuzumab deruxtecan (Enhertu), a ...